Regeneration Technologies, Inc.,

Regeneration Technologies, Inc., together with its subsidiaries, processes human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, and dermal tissue to produce allografts. It also process bovine tissue to produce Sterling xenograft line of products. The company’s products are used in healing various bone and other tissue defects, including spinal vertebrae repair, musculoskeletal reconstruction, fracture repair, repairs to the jaw, and related tissues, as well as heart valve disorders. Its product portfolio comprises spinal allografts that include precision tooled implants utilized in spinal procedures; sports medicine allografts, which are tendons for ligament reconstruction and its meniscal allografts for transplantation; allograft paste implants used in fracture treatment, bone and joint reconstruction, and periodontal applications; and blended and milled bone allografts used in hip and knee replacements. The company also offers cardiovascular allograft, a heart valve allograft, which is used by surgeons to replace a patient’s own heart valve during coronary surgery; conventional allografts used for cancer treatment procedures, and hip and knee reconstruction; and fashioned bones, such as wedges, strips, and shafts used in various orthopedic and sports medicine procedures. It distributes its products in the United States, Korea, and Europe. The company was founded in 1997 and is based in Alachua, Florida.